We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Passage Bio
PASG
$14.1M
| $469K | ﹤0.01% |
2,355
+86
| +4% | +$20.5K |
|
2577
Utah Medical Products
UTMD
$225M
| $468K | ﹤0.01% |
5,046
+175
| +4% | +$15.5K |
|
2578
Stoke Therapeutics
STOK
$2.11B
| $466K | ﹤0.01% |
18,319
+849
| +5% | +$23.7K |
|
|
NPKI
2579
NPK International
NPKI
$1.14B
| $466K | ﹤0.01% |
141,235
-840
| -0.6% | -$2.37K |
|
2580
BioXcel Therapeutics
BTAI
$27.8M
| $465K | ﹤0.01% |
957
+51
| +6% | +$22.4K |
|
2581
Peoples Financial Services
PFIS
$707M
| $464K | ﹤0.01% |
10,172
-11
| -0.1% | -$489 |
|
2582
Traeger
COOK
$172M
| $462K | ﹤0.01% |
+441
| New | +$550K |
|
2583
MeiraGTx Holdings
MGTX
$1.21B
| $461K | ﹤0.01% |
35,014
+1,400
| +4% | +$19.2K |
|
|
NEUE
2584
DELISTED
NeueHealth
NEUE
| $461K | ﹤0.01% |
+706
| New | +$621K |
|
2585
Hooker Furnishings Corp
HOFT
$166M
| $459K | ﹤0.01% |
17,011
+352
| +2% | +$11.3K |
|
|
TBCH
2586
Turtle Beach Corp
TBCH
$277M
| $457K | ﹤0.01% |
16,412
+685
| +4% | +$20K |
|
2587
Citizens
CIA
$192M
| $456K | ﹤0.01% |
73,483
-797
| -1% | -$4.53K |
|
2588
Airbnb
ABNB
$107B
| $455K | ﹤0.01% |
2,713
+617
| +29% | +$94.2K |
|
2589
Carter Bankshares
CARE
$731M
| $455K | ﹤0.01% |
31,975
+1,955
| +7% | +$24.1K |
|
2590
Intrepid Potash
IPI
$469M
| $455K | ﹤0.01% |
14,714
+545
| +4% | +$17.1K |
|
|
RYZ
2591
Ryerson Holding Corp
RYZ
$1.46B
| $455K | ﹤0.01% |
20,428
+544
| +3% | +$10.7K |
|
2592
Tilly's
TLYS
$128M
| $454K | ﹤0.01% |
32,425
+1,160
| +4% | +$17.6K |
|
2593
Select Water Solutions
WTTR
$2.61B
| $453K | ﹤0.01% |
87,376
+2,294
| +3% | +$12.6K |
|
2594
Frontier Group Holdings
ULCC
$1.7B
| $452K | ﹤0.01% |
28,653
+1,578
| +6% | +$24.4K |
|
2595
Cartesian Therapeutics
RNAC
$268M
| $450K | ﹤0.01% |
3,605
+98
| +3% | +$11.8K |
|
2596
Theravance Biopharma
TBPH
$877M
| $450K | ﹤0.01% |
60,849
+2,438
| +4% | +$27.3K |
|
2597
IES Holdings
IESC
$15.2B
| $449K | ﹤0.01% |
9,817
+110
| +1% | +$5.35K |
|
|
EGIO
2598
DELISTED
Edgio, Inc. Common Stock
EGIO
| $449K | ﹤0.01% |
4,717
-24
| -0.5% | -$2.53K |
|
|
BNFT
2599
DELISTED
Benefitfocus, Inc.
BNFT
| $449K | ﹤0.01% |
40,495
+1,048
| +3% | +$12.7K |
|
2600
i3 Verticals
IIIV
$342M
| $447K | ﹤0.01% |
18,465
+952
| +5% | +$27.5K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.